Anti-neutrophil cytoplasmic antibody-associated systemic vasculitis: Nature or nurture?

Internal Medicine Journal

Volumn 42, Issue 4, 2012, Pages 351-359

  Gatenby, P A ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Anti neutrophil cytoplasmic antibody; Genetics; Silica; Vasculitis; Vitamin D

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

AGE DISTRIBUTION; ECOLOGY; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENETICS; HUMAN; INFECTION; LATITUDE; NECROTIZING ARTERITIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RURAL AREA; SEX DIFFERENCE; SYNTHESIS; SYSTEMIC VASCULITIS; URBAN AREA;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ENVIRONMENTAL EXPOSURE; HUMANS; RISK FACTORS;

EID: 84859828872     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02705.x     Document Type: Review

References (70)

1. Jenette JC, Falk RJ. Nosology of primary vasculitis. Curr Opin Rheumatol 2007; 19: 10-16.
2. Kallenberg CGM. Antineutrophil cytoplasmic autoantibody-associated small vessel vasculitis. Curr Opin Rheumatol 2007; 19: 17-24.
3. Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF etal. The American College of Rheumatology 1990 criteria for the classification of vasculitis: introduction. Arthritis Rheum 1990; 33: 1065-67.
4. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL etal. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
5. Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis - is it time to reclassify? Rheumatology (Oxford) 2011; 50: 643-5.
6. Kallenberg CGM. Pathophysiology of ANCA-associated small velssel vasculitis. Curr Rheumatol Rep 2010; 12: 399-405.
7. Wilde B, van Paassen B, Witzke O, Tervaert JWC. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 2011; 79: 599-612.
8. de Lind van Wijngaarden RAF, van Rijn L, Hagen EC, Watts RA, Gregorini G, Tervaert JWC etal. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody-associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol 2008; 3: 237-52.
9. Gibelin A, Maldini C, Mahr A. Epidemiology and etiology of Wegener granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, Goodpasture syndrome: vasculitides with frequent lung involvement. Semin Respir Crit Care Med 2011; 32: 264-73.
10. Popa ER, Cohen Tervaert JW. The relationship between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions. Intern Med 2003; 42: 771-80.
11. Kain R, Exner M, Brandes R, Ziebemayr R, Cunningham D, Davidovits A etal. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14: 1088-96.
12. Reinhold-Keller E, Zeidler A, Gutfleisch J, Peter HH, Rapse HH, Gross WL. Giant cell arteritis is more prevalent in urban than rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) 2000; 39: 1396-402.
13. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gutfleisch J, Peter HH, Raspe HH etal. No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology (Oxford) 2002; 41: 540-49.
14. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005; 53: 93-9.
15. Carruthers DM, Watts RA, Symmons DPM, Scott DGI. Wegener's granulomatosis - increased incidence or increased recognition? Br J Rheumatol 1996; 35: 142-5.
16. Watts RA, Lane SE, Bentham G, Scott DGI. Epidemiology of systemic vasculitis. A ten year study in the United Kingdom. Arthritis Rheum 2000; 43: 414-19.
17. González-Gay MA, García-Porrúa C. Systemic vasculitis in adults in northwest Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore) 1999; 78: 292-308.
18. Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in north-west Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49: 388-93.
19. Knight A, Ekbom A, Brandt L, Askling J. Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001. J Rheumatol 2006; 33: 2060-63.
20. Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum 2000; 43: 2481-7.
21. Dadoniene J, Kirdaite G, Mackiewicz Z, Rimkevicius A, Haugeberg G. Incidence of primary systemic vasculitis in Vilnius: a university hospital population based study. Ann Rheum Dis 2005; 64: 335-6.
22. Zeft A, Schlesinger M, Weiss N, Emery H. Case control study of ANCA associated vasculitis in Western Montana. Arthritis Rheum 2005; 52(Suppl 9): S648.
23. Sanchez-Torres AA, Acevedo-Vasquez EM, Sanchez-Schwartz CG, Pastor-Asurza CA, Perich-Campos RA, Alfaro-Lozano JL etal. Epidemiology of the primary systemic vasculitides in a Latin-American population. Clin Exp Rheumatol 2007; 25(Suppl 44): S95.
24. Ormerod AS, Cook MC. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern Med J 2008; 38: 816-23.
25. Fujimoto S, Uezono S, Hisanaga S, Fukedome K, Koyabayashi S, Suzuki K etal. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 2006; 1: 1016-22.
26. El-Reshaid K, Kapoor MM, El-Reshaid W, Madda JP, Varro J. The spectrum of renal disease associated with microscopic polyangiitis and classic polyarteritis nodosa in Kuwait. Nephrol Dial Transplant 1997; 12: 1874-82.
27. O'Donnell JL, Stevanovic VR, Frampton C, Stamp LK, Chapman PT. Wegener's granulomatosis in New Zealand: evidence for a latitude dependent gradient. Intern Med J 2007; 37: 242-6.
28. Haugeberg G, Bie R, Benvold A, Storm Larsen A, Johnsen V. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 1998; 17: 364-8.
29. Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multi-ethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51: 92-9.
30. Mohammad AJ, Jacobsson LTH, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology(Oxford) 2007; 46: 1329-37.
31. Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener's granulomatosis. Arthritis Rheum 1996; 39: 87-92.
32. Gibson A, Stamp LK, Chapman PT, O'Donnell JL. The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a southern hemisphere region. Rheumatology (Oxford) 2006; 45: 624-8.
33. Watts RA, Scott DGI, Fujimoto S, Kobayashi S, Suzuki K, Shigeto S etal. Epidemiology of renal ANCA-associated vasculitis in the UK and Japan. Clin Exp Rheumatol 2007; 25(Suppl 44): S95.
34. Jacobson DL, Grange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223-43.
35. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990; 113: 656-63.
36. Lane SE, Scott DGI, Heaton A, Watts RA. Primary renal vasculitis in Norfolk - increasing incidence or increasing recognition? Nephrol Dial Transplant 2000; 15: 23-7.
37. Tidman M, Orlander R, Svalander C, Danielsson D. Patients hospitalised because of small vessel vasculitides with renal involvement in the period 1975-1995: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med 1998; 244: 133-41.
38. Watts RA, Mooney J, Mukhtyar C, Skinner J, MacGregor A, Scott DGI. Contrasting epidemiology of WG and MPA. Clin Exp Immunol 2011; 164(Suppl 1): 73.
39. Raynauld JP, Bloch DA, Fries JF. Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis. J Rheumatol 1993; 20: 1524-6.
40. Mahr A, Artigues N, Coste N, Aouba A, Pagnoux C, Guillevin L etal. Seasonal variations in onset of Wegener's granulomatosis: increase in summer? J Rheumatol 2006; 33: 1615-22.
41. Lane SE, Watts RA, Scott DGI. Seasonal variations in onset of Wegener's granulomatosis: increased in summer? J Rheumatol 2007; 34: 889-90.
42. Gatenby PA, Lucas RM, Engelsen O, Ponsonby A-L, Clements M. Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation? Arthritis Rheum (Arthritis Care Res) 2009; 61: 1417-24.
43. Peelen E, Knippenberg S, Muris A-H, Thewisson M, Smolders J, Tervaert JWC etal. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev 2011; 10: 733-43.
44. Steenland K. One agent, many diseases: exposure-response data and comparative risks of different outcomes following silica exposure. Am J Ind Med 2005; 48: 16-23.
45. Yashiro M, Muso E, Itoh-Ihara T, Oyama A, Hashimoto K, Kawanura T etal. Significantly high regional morbidity of MPO-ANCA-related angiitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe(Japan). Am J Kidney Dis 2000; 35: 889-95.
46. Cuellar ML. Drug-induced vasculitis. Curr Rheumatol Rep 2002; 4: 55-9.
47. Yu F, Chen M, Gao Y, Wang SX, Zou WZ, Zhao MH etal. Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. Am J Kidney Dis 2007; 49: 607-14.
48. Short AK, Lockwood CM. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. Q J Med 1995; 88: 775-83.
49. Gao Y, Chen M, Ye H, Guo XH, Zhao MH, Wang HY. The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil. Int Immunopharmacol 2007; 7: 55-60.
50. Jamaleddine G, Diab K, Tabbarah Z, Tawil A, Arayssi T. Leukotiene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum 2002; 31: 218-27.
51. Kranke B, Aberer W. Macrolide-induced Churg-Strauss syndrome in patient with atopy. Lancet 1997; 350: 1551-2.
52. Hubner C, Dietz A, Stremmel W, Stiehl A, Andrassy H. Macrolide-induced Churg-Strauss syndrome in a patient with atopy. Lancet 1997; 350: 563.
53. Dietz A, Hubner C, Andrassy K. Macrolide induced vasculitis (Churg-Strauss syndrome). Laryngorhinootologie 1998; 77: 111-14.
54. Rodriguez-Pla A, Stone JH. Vasculitis and systemic infections. Curr Opin Rheumatol 2006; 18: 39-47.
55. Popa ER, Stegeman CA, Abdulahad B, van der Meer B, Manson WM, Bos NA etal. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46: 1029-33.
56. Leung DY, Schlievert PM, Meissner HC. The immunopathogenesis and management of Kawasaki syndrome. Arthritis Rheum 1998; 41: 1538-47.
57. Preston GA, Roth AJ, Brown MC, Badhwar AK, Chung HC, McGregor JG etal. Is LAMP-2 a target of ANCA? Clin Exp Immunol 2011; 164(Suppl 1): 46.
58. Stegman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335: 16-20.
59. Hamidou MA, Audrain M, Ninin E, Robillard N, Muller J-Y, Bonneville M. Staphylococcus aureus, T cell repertoire, and Wegener's granulomatosis. Joint Bone Spine 2001; 68: 373-7.
60. Knight A, Sandin S, Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. Arthritis Rheum 2008; 58: 302-7.
61. Heckmann M, Holle JU, Arning LO, Knaup S, Hellmich B, Nothnagel M etal. The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP typing. Ann Rheum Dis 2008; 67: 972-9.
62. Wieczorek S, Holle JU, Epplen JT. Recent progress in the genetics of Wegener's granulomatosis and Churg-Strauss syndrome. Curr Opin Rheumatol 2010; 22: 8-14.
63. Tsuchyia N, Kobayashi S, Kawasaki A, Kyoogoku C, Arimura Y, Tokunaga K etal. Genetic background of Japanese patients with antineutrophil cytoploasmic antibody associated vasculitis: association of HLA-DRB1*0901 with microscopic angiitis. J Rheumatol 2003; 30: 1534-40.
64. Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A etal. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 2007; 56: 3159-66.
65. Vang T, Miletic AV, Arimura Y, Tautz L, Rickert RC, Mustelin T. Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol 2008; 26: 29-55.
66. Mahr AD, Edberg JC, Stone JH, Hoffman GS, StClair EW, Specks U etal. Alph1-antitrypsin deficiency related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis Rheum 2010; 62: 3760-67.
67. Lamprecht P, Wieczorek S, Epplen JT, Ambrosch P, Kallenberg CGM. Granuloma formation in ANCA-associated vasculitides. APMIS 2009; 117(Suppl 127): 32-6.
68. Morgan MD, Day CJ, Piper KP, Khan N, Harper L, Moss PA etal. Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 2010; 130: 64-73.
69. Willcocks LC, Lyons PA, Rees AJ, Smith KGC. The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Res Ther 2010; 12: 202-13.
70. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 2011; 365: 1612-23.